Vancouver, British Columbia – (September 14th, 2020) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that 2 of its most recent abstract submissions for the Novel Technology Application in Cancer Prevention and Early Detection Spark Grants competition have resulted in invitations to submit full applications for funding. This comes after the organizers of the competition, the Canadian Cancer Society/Canadian Institutes of Health Research – Institute of Cancer Research, and Brain Canada Foundation, evaluated the abstracts for their relevance to funding opportunities in the prevention and early detection of cancer.


BioMark would like to thank Dr. David Wishart and his TMIC (The Metabolomics Innovation Centre) team for their abstract which focused on the use of a robust panel of biomarkers for potential early lung cancer screening. In addition, Dr. Horacio Bach’s (University of British Columbia) abstract relates to the development of an affordable enzyme-linked immunoassay (ELISA) kit which are commonly used in laboratories for clinical diagnosis. This customized ELISA kit has been developed using highly specific monoclonal antibodies and tested against industry gold standard Liquid-chromatography-tandem-mass-spectrometry (LC-MS/MS) for potential cancer screening application ideally suited for remote settings. “We have been working with both Drs. Wishart and Bach over the years and are delighted to be associated with them and look to support them to submit their full application due by mid October.  We are excited to be part of this competitive application which seeks to support next generation of disruptive technologies in cancer”, says BioMark CEO Rashid Bux.


About Sparks Grant

The Canadian Cancer Society (CCS), the Canadian Institutes of Health Research – Institute of Cancer Research (CIHR-ICR), and Brain Canada Foundation (BC or Brain Canada) have committed a total of up to $2.4M over one year to jointly fund Spark Grants focused on Novel Technology Applications in Cancer Prevention and Early Detection.


The intent of the Novel Technology Application in Cancer Prevention and Early Detection program is to “spark” and accelerate new activity in the development and/or application of truly novel approaches to cancer prevention and early detection. To accelerate progress and uptake in cancer prevention and early detection in the short- to medium-term, CCS, CIHR-ICR and BC are launching this funding opportunity to support Spark Grants designed to gather pilot data to drive the application of truly innovative new technologies, or the novel repurposing of existing technologies into the study of cancer prevention and early detection.


Spark Grants will support preliminary research to establish proof of principle in novel cancer prevention and early detection approaches. The goal is to fund high risk, high reward studies, that provide sufficient rationale and/or preliminary data to convince reviewers of the novelty and feasibility of the proposed work. Spark Grants are intended to support the development of new partnerships and the exploration of highly novel concepts, involving researchers from any research area, and particularly from non-traditional cancer fields, such as engineering, AI, robotics, physics, nanoscience, statistics, informatics, computer and data sciences, behavioural science, and any other discipline poised to seed the next generation of disruptive technologies in cancer.



Vancouver, British Columbia – (August 27th, 2020) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that Health Canada has approved its clinical trial application (CTA) and has granted a Letter of No Objection (NOL) for its application entitled ACETYL-AMANTADINE AS A BIOMARKER IN PATIENTS WITH GLIOBLASTOMA.


The company would like to thank Dr. Marshall Pitz the principal investigator and is the Section Head of Clinical Research at the Research Institute at CancerCare Manitoba (CCMB) and other co- PIs that include Dr. Donald Miller, Dr. Thomas Klonisch, Dr. Marco Essig, Dr. David Wishart, Dr. Ted Lakowsky and Dr. Anmol Mann for their excellent effort in developing the protocol, submitting it to ethics review board (ERB) and eventually securing the NOL so that BioMark team can commence the trials by October. “Assembling a high impact multi- disciplinary team to collaborate in developing this potentially disruptive diagnostic test that can improve identification and care for patients with glioblastoma is exciting and critically required to positively impact treatment care for patients suffering with Glioblastoma”, says CEO Rashid Bux.


About Glioblastoma Multiforme (GBM)

The most common primary brain tumour in adults is glioblastoma (GBM). Originating from transformed neural precursor cells, GBM is a highly aggressive and infiltrative brain tumour.  The death rate of GBM worldwide is approximately 225,000 per year (1).  While GBM has a lower incidence than many other cancers, the prognosis is particularly poor with average survival from time of diagnosis being approximately 14-16 months (2, 3).  Furthermore, compared to other cancers such as breast cancer, which have seen significant advancements in treatment and increased survival, the survival rates for GBM remain similar to those 30 years ago (4).

Monitoring of tumour response is typically through magnetic resonance imaging (MRI) of the brain, conducted every 2-3 months. The poor prognosis associated with GBM is a combination of lack of early detection, incomplete surgical resections of tumour mass and ineffective postsurgical treatment options.  Thus, the ability to detect GBM while the patient is still asymptomatic is likely to create a positive ripple effect with improvements in both the surgical resection and radiation and chemotherapeutic outcomes.  Perhaps an even more profound impact of the proposed study is the potential use as a diagnostic drug biomarker to monitor GBM progression during treatment and early detection of tumour re-occurrence. Thus, a reliable and affordable diagnostic agent that could monitor therapeutic response in GBM patients would allow the clinician and patient to move to new therapies more quickly. The glioblastoma (GBM) market is expected to grow from $662.0m in 2017 to $1.4bn in 2027 across the eight major markets (8MM*) at a compound annual growth rate (CAGR) of 7.5%, according to GlobalData.


  1. Alphandery E. (2018). Glioblastoma treatments: An account of recent industrial developments. Front. Pharmacol. 9:879.
  2. Thakkar JP, Dolecek TA, Horbinski C, Ostrom QT, Lightner DD, Barnholtz-Sloan JS, and Villano JL. (2014). Epidemiologic and molecular prognostic review of glioblastoma. Cancer Epidemiol. Biomarkers Prev. 23:1985-1996.
  3. Carlsson SK, Brothers SP, and Wahlestedt C. (2014). Emerging treatment strategies for glioblastoma multiforme. EMBO Mol. Med. 6:1359-1370.
  4. Fine HA. (2015). New strategies in glioblastoma: exploiting the new biology. Clin Cancer Res. 21:1984-1988.


BioMark Diagnostics Expands Research Development in Quebec

Vancouver, British Columbia – (August 13th, 2020) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF), a developer of proprietary, non-invasive, and accurate diagnostic solutions announced today that the Company is moving parts of its lung cancer research and development operations to LE CAMP,  an incubator-accelerator dedicated to tech businesses growth and mentorship.


“This move highlights BioMark’s focus on diagnostic development and technological innovation within the healthcare sector,” said Rashid Bux, Chief Executive Officer of BioMark Diagnostics Inc  “The renowned LE CAMP site  offers a diversity of services adapted to similarly sized development stage companies and offers a significant opportunity to form strategic relationships with other industry leaders.  Going forward we intend to invest in human capital and expand our infrastructure in Quebec in order to accelerate the commercialization of our early lung cancer detection platform with IUCPQ (l’Institut universitaire de cardiologie et de pneumologie de Québec) and other excellent strategic partners located across the province. Our institutions have been engaged in clinical studies that have led to very exciting results for potential lung cancer screening.”


BioMark’s research and development is based on the science of metabolomics and leverages Artificial intelligence (AI) systems that make advances in omics and molecular technologies, such as liquid biopsy, faster and more accurate. The Company focuses on the pivotal role that metabolomics plays in early cancer detection with an aim to improve patient treatment outcome. Metabolomics gives you a precise chemical read out on a person’s state of health since it involves the rapid, high throughput characterization of the small molecule metabolites found in an organism.  Additionally, BioMark is targeting a Covid-19 screening, which is focused on fundamentally changing how testing will be done on a global basis.


About Le Camp


A cornerstone of Québec City’s business community, LE CAMP is a vibrant home where ideas flourish and successful businesses are born. LE CAMP is an incubator-accelerator dedicated to growing tech businesses and guiding their creative projects. Located in the Saint-Roch neighborhood in the heart of Québec City, it gives access to acceleration and incubation programs, as well as improvement and networking activities. LE CAMP is managed and led by Québec International, Québec’s metropolitan economic development agency. For more information, please visit

Press Release – BioMark Diagnostics Expands Research Development in Quebec

BioMark’s Affiliated Company, Bio-Stream Diagnostics Inc. Announces Partnership with Qatar University ML Team for Development of COVID-19 Testing

The Company will leverage Raman spectroscopy and Machine Learning as part of its diagnostics


Vancouver, British Columbia – (July 21, 2020) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) announced today that its affiliated company, Bio-Stream Diagnostics Inc.,  will be working with University of Qatar’s Dr. Somaya Al-Maadeed in the development of its novel COVID-19-detection method, leveraging new generation Raman spectroscopy and the power of machine learning. Raman spectroscopy is a spectroscopic technique typically used to determine vibrational modes of molecules, although rotational and other low-frequency modes of systems may also be observed. Raman spectroscopy is commonly used in chemistry to provide a structural fingerprint by which molecules can be identified.


Professor Al- Maadeed heads the Computer Science and Engineering Department at Qatar University with research interests in Pattern Recognition, Image and Signal Processing, AI, Bio-Metrics, Character Recognition, Writer Identification, and Digital Library. Prof Al-Maadeed is a recent recipient of a grant from Qatar University’s Predicting Risk Early in COVID-19 -The PERIL Study which fits very well with Bio- Stream’s research and future commercialization objectives.


“We are delighted to have Professor Al- Maadeed and her dedicated group from Qatar University to be part of our research team with a special focus on the use of ML in rapid COVID -19 diagnosis,” said Mr. Rashid A. Bux, President & CEO of BioMark Diagnostics, Inc.  “The additional ML resources and talent that both Professor Al-Maadeed and Qatar University provide will complement our already strong ML group. This collaboration demonstrates our global intent to partner with leading institutions and organizations that are seeking ways to bringing in rapid, effective and economical COVID -19 screening solutions to market.”


About Qatar University

Since its inception in 1977, Qatar University (QU) continues to serve as Qatar’s primary institution of higher education and has become today a beacon of academic and research excellence in the region.  QU hosts ten colleges — College of Arts and Sciences (CAS), College of Business and Economics (CBE), College of Education (CED), College of Engineering (CENG), College of Health Sciences (CHS), College of Law (LAWC), College of Medicine (CMED), College of Pharmacy (CPH), College of Sharia and Islamic Studies (CSIS) and College of Dental Medicine (CDM).  Research is an integral part of the academic environment at QU and is bolstered by the state-of-the-art Research Complex, and 14 research centers of excellence. It is further enhanced by over 400 collaborative projects in over 130 countries.

Community engagement is an area stationed at the heart of QU’s mission and vision. The University prides itself on the quality of its students and alumni and is committed to ensuring that campus life is an enriching environment for encouraging academic excellence, volunteerism, civic responsibility, and leadership.  QU is advancing its goal to become a leader of economic and social development in Qatar through collaborations and partnerships with industry, government, academia, business, and civil society in Qatar and beyond.


Press Release – BioStream Diagnostics Inc. Collaborates with Qatar University